How have immune checkpoint inhibitors transformed melanoma treatment?

Immune checkpoint inhibitors (ICIs) have had a significant impact on the prognosis of people with a wide range of tumours. Melanoma in particular is one of the malignancies for which immunotherapy can achieve excellent outcomes in the adjuvant and advanced settings. Here the authors discuss the use of ICIs and the benefits they can offer.

Automated summary

Immune checkpoint inhibitors have had a significant impact on the prognosis of patients with various tumors, especially for melanoma patients who can achieve excellent outcomes with immunotherapy in both the adjuvant and advanced stages.